Evidence map›Paper›PMID 25221657›Full record

ArticleACS medicinal chemistry letters2014

2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.

Maruti Naik, Sandeep Ghorpade, Lalit Kumar Jena, Gopinath Gorai, Ashwini Narayan, Supreeth Guptha, Sreevalli Sharma, Neela Dinesh, Parvinder Kaur, Radha Nandishaiah and 9 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. An arylsulfonamide that targets cell wall biosynthesis inAntimicrobial agents and chemotherapy · 2024
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Maruti NaikDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Sandeep GhorpadeDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Lalit Kumar JenaDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Gopinath GoraiDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Ashwini NarayanDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Supreeth GupthaDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Sreevalli SharmaDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Neela DineshDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Parvinder KaurDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Radha NandishaiahDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Jyothi BhatDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Gayathri BalakrishnanDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Vaishali HumnabadkarDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Vasanthi RamachandranDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Lava Kumar NaviriDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Pallavi KhadtareDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Manoranjan PandaDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Pravin S IyerDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.
Monalisa ChatterjiDepartment of Medicinal Chemistry and Department of Biosciences, IMED Infection, AstraZeneca , Bellary Road, Hebbal, Bangalore 560024, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A cellular activity-based screen on Mycobacterium tuberculosis (Mtb) H37Rv using a focused library from the AstraZeneca corporate collection led to the identification of 2-phenylindoles and arylsulphonamides, novel antimycobacterial scaffolds. Both the series were bactericidal in vitro and in an intracellular macrophage infection model, active against drug sensitive and drug resistant Mtb clinical isolates, and specific to mycobacteria. The scaffolds showed promising structure-activity relationships; compounds with submicromolar cellular potency were identified during the hit to lead exploration. Furthermore, compounds from both scaffolds were tested for inhibition of known target enzymes or pathways of antimycobacterial drugs including InhA, RNA polymerase, DprE1, topoisomerases, protein synthesis, and oxidative-phosphorylation. Compounds did not inhibit any of the targets suggesting the potential of a possible novel mode of action(s). Hence, both scaffolds provide the opportunity to be developed further as leads and tool compounds to uncover novel mechanisms for tuberculosis drug discovery.

Indexed as

2-phenylindolesarylsulphonamidesMycobacterium tuberculosisTuberculosis

Identifiers

PMID25221657
PMCPMC4160756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.